Adjuvant Therapy with Pembrolizumab in Renal Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Adjuvant pembrolizumab showed 64.2% disease-free survival in real-world renal cell carcinoma patients. However, M1NED patients had higher recurrence rates and earlier onset compared to clinical trials.
Area Of Science
- Oncology
- Nephrology
- Clinical Trials
Background
- Adjuvant pembrolizumab demonstrated improved disease-free survival (DFS) in high-risk renal cell carcinoma (RCC) patients post-nephrectomy in the KEYNOTE-564 trial.
- Real-world data is crucial to validate findings from clinical trials in diverse patient populations.
Purpose Of The Study
- To evaluate the efficacy and safety of adjuvant pembrolizumab in a real-world RCC cohort.
- To compare real-world outcomes with those reported in the KEYNOTE-564 trial.
Main Methods
- Multicenter retrospective study including RCC patients receiving adjuvant pembrolizumab from January 2022 to October 2023.
- Assessment of disease-free survival (DFS) and treatment safety, including adverse events and treatment discontinuations.
Main Results
- Fifty-two RCC patients were included, with varying risk classifications (intermediate-high risk, high risk, M1 with no evidence of disease).
- Overall DFS at 6 months was 64.2%. M1NED patients showed significantly lower DFS compared to non-metastatic patients (p = 0.025).
- Grade 3 or higher adverse events occurred in 26% of patients, with 20% discontinuing treatment.
Conclusions
- Real-world recurrence rates in M1NED patients were high and occurred earlier than observed in the KEYNOTE-564 trial.
- Long-term toxicities associated with adjuvant pembrolizumab were comparable to clinical trial data.
- Adjuvant pembrolizumab demonstrates a potential benefit in real-world RCC settings, though careful monitoring for M1NED patients is warranted.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
